Compare NBTX & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBTX | RAPP |
|---|---|---|
| Founded | 2003 | 2022 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2020 | 2024 |
| Metric | NBTX | RAPP |
|---|---|---|
| Price | $21.60 | $26.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $8.00 | ★ $47.80 |
| AVG Volume (30 Days) | 32.1K | ★ 315.6K |
| Earning Date | 09-30-2025 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,930,711.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $145.24 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.95 | $6.43 |
| 52 Week High | $30.35 | $42.27 |
| Indicator | NBTX | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 50.84 | 43.19 |
| Support Level | $21.01 | $25.66 |
| Resistance Level | $21.41 | $28.42 |
| Average True Range (ATR) | 0.83 | 1.73 |
| MACD | 0.02 | -0.17 |
| Stochastic Oscillator | 69.93 | 15.01 |
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.